Press Releases

October 27, 2022 – Life Science Newswire – Ardigen, one of the world’s leading artificial intelligence (AI) companies advancing precision medicine, has announced that it is supporting the Joint Undertaking in Morphological Profiling-Cell Painting (JUMP-CP) Consortium with its technology and expertise. The consortium of 10 leading pharmaceutical companies and two non-profit research organizations including the Broad Institute of MIT and Harvard, is focused on creating data, validation, and technical know-how to transform drug discovery with Cell Painting technology.

The JUMP-CP Consortium’s aim is to validate and scale up image-based drug discovery strategies by creating the world’s largest public cell imaging data set corresponding to both genetic and chemical perturbations. This valuable public resource brings with it hope of reducing the major bottleneck in drug discovery: determining the mechanism of action for drug candidates. Other significant applications include predicting compounds’ activity and toxicity, as well as matching drugs to disease states.

Ardigen’s primary scope of research within the JUMP-CP Consortium is aimed at improving the predictive power of the JUMP-CP data by expanding the applicability domain of machine learning models that predict assay activity based on Cell Painting images. Another important contribution of Ardigen is to facilitate the JUMP-CP data exploration by providing a web application that allows scientists to easily search for similarities between various phenotypes and the corresponding genetic and chemical perturbations.

"We are pleased to welcome Ardigen as a Supporting Partner of the JUMP Cell Painting Consortium, and I look forward to the insights gained from focusing their deep learning expertise on the Consortium’s one-of-a-kind Cell Painting dataset."

-        Anne Carpenter, Ph.D., Senior Director of the Imaging Platform at the Broad Institute.

“We are very excited about supporting the JUMP Cell Painting Consortium with Ardigen’s technology and expertise. I do believe that our joint efforts with the leading pharmaceutical companies and non-profit research organizations will result in a significant improvement of the image-based drug discovery strategy.”

-        Michał Warchoł, Ph.D., Executive Vice President at Ardigen. 

About Ardigen

Ardigen is harnessing advanced AI methods for novel precision medicine. The company accelerates therapy development by designing immunity, decoding microbiomes, analyzing biomedical images, and providing digital drug discovery services. Ardigen’s team is rooted in biology and has extensive expertise in bioinformatics, machine learning, and software engineering. The company’s in-house datasets, together with advanced AI platforms, empower the development of effective precision therapies.

About the JUMP-CP Consortium

Funded in part by the Bits to Bytes Capital Call of the Massachusetts Life Sciences Center (MLSC), the JUMP-Cell Painting Consortium is creating a new data-driven approach to drug discovery based on cellular imaging, image analysis, and high-dimensional data analytics. We believe it will transform drug discovery by relieving a major bottleneck in the pharma pipeline: determining the mechanism of action of potential therapeutics prior to introduction into patients. We will soon release our unprecedented public data set to validate and scale up this image-based drug discovery strategy. This valuable public resource will then be available for other applications, including predicting compounds’ activity and toxicity, matching drugs to disease states, and more.

More information at ardigen.com